Description

Overview

Semaglutide is a long-acting analog of glucagon-like peptide-1 (GLP-1) designed for prolonged receptor activation. It has an extensive human clinical literature in type 2 diabetes, chronic weight management, and cardiovascular-risk research. Mechanistically, GLP-1 receptor activation influences glucose-dependent insulin secretion, glucagon signaling, appetite-related central pathways, and gastrointestinal motility. FDA approvals apply to specific manufactured prescription products such as Ozempic, Wegovy, and Rybelsus—not to separately sold research material.

How It Works

• GLP-1 receptor activation: Enhances glucose-dependent insulin signaling and suppresses inappropriate glucagon secretion.
• Central appetite signaling: GLP-1 pathways in the brain influence hunger, satiety, and food intake.
• Gastrointestinal signaling: The drug class can slow gastric emptying, especially during early exposure.

Research Areas

• Type 2 diabetes
• Chronic weight management
• Cardiovascular outcomes
• Metabolic and liver-related research

Research / Study Context

• STEP program: Large randomized obesity trials measured body weight, cardiometabolic markers, and safety.
• SUSTAIN / cardiovascular programs: Diabetes and cardiovascular trials evaluated glycemic and major cardiovascular outcomes.

Key Research Findings

• Semaglutide has one of the largest clinical evidence bases in this product list.
• Benefits and risks are product- and indication-specific.
• Apex RUO material must not be represented as Ozempic, Wegovy, Rybelsus, or a substitute for them.

Related Research

• Tirzepatide
• Retatrutide
• Cagrilintide

Scientific Reference Starter Set

• Peptide Education Hub: Semaglutide profile
• PubMed: STEP 1 semaglutide obesity trial
• FDA prescribing information: Ozempic / Wegovy / Rybelsus